Aralez has acquired the U.S. and Canadian rights to cardiovascular drug Zontivity from Merck.
On September 7, Willkie client Aralez Pharmaceuticals Inc. announced that it has acquired the U.S. and Canadian rights to Zontivity (vorapaxar) from Merck.
Zontivity is the first and only approved therapy shown to inhibit the protease-activated receptor-1 (PAR-1), the primary receptor for thrombin, which is considered to be the most potent activator of platelets. In the United States, Zontivity is indicated for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD). In Canada, Zontivity (vorapaxar sulfate) is indicated for the reduction of atherothrombotic events in adult high-risk patients with a history of myocardial infarction (MI).
Aralez Pharmaceuticals Inc. is a global specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas.
The deal was handled by partners Adam Turteltaub, Russell Leaf, David Tarr, Thomas Meloro and Christopher Peters; and associates Vanida Narrainen, Thomas Sharkey, Mia Ellis and Rachel Dooley.